A recent report published by Infinium Global Research on hypercholesterolemia drugs market provides in-depth analysis of segments and sub-segments in global as well as regional hypercholesterolemia drugs market. The study also highlights the impact of drivers, restraints and macro indicators on the global and regional hypercholesterolemia drugs market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global hypercholesterolemia drugs market. According to the report the global hypercholesterolemia drugs market is projected to grow at a CAGR of 4.7% over the forecast period of 2018-2024.
The presence of a high level of cholesterol in the blood is known as hypercholesterolemia or high cholesterol. Fatty deposits in the walls of the coronary arteries are formed due to excess cholesterol present in the blood. As the cholesterol accumulates, it causes atherosclerotic plaques to form, which narrows and hardens the artery walls and reduces the supply of blood to the heart. This increases the risk of angina and heart attack. High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, very low-density lipoprotein (VLDL) cholesterol are the types of Human blood cholesterol.
Growing responsiveness to heart diseases associated with the aging population is the key factor driving the growth of the market. Additionally, availability of funding and activities to promote health awareness programs by healthcare centers, rise in the incidence of cardiovascular diseases and increasing awareness among people for reducing the harmful cholesterol levels to control heart diseases such factors are likely to boost the growth in this market.
Statins are expected to be the largest segment among the drug class in 2016. Statins help to reduce blood cholesterol levels, bring down the danger of chest pain, heart attack, and stroke caused by a blocked blood vessel. Among the geographies, North America is expected to be the largest market for hypercholesterolemia drugs due to increasing incidences of heart diseases and related disorders in the region. While, Asia-Pacific is expected to grow fast during the forecast period, owing to the presence of a large pool of patient and growing government initiatives in countries like China and India is likely to augment the growth in this region.
The report on global hypercholesterolemia drugs market covers segments such as drug class, type of disease and mechanism of action. On the basis of drug class, the global hypercholesterolemia drugs market is categorized into statins and non-statins. On the basis of the type of disease the global hypercholesterolemia drugs market is categorized into FH and non-FH. On the basis of the mechanism of action the global hypercholesterolemia drugs market is categorized into bile acid sequestrants, HMG-CoA reductase inhibitors, fibric acid derivatives, nicotinic acid, and others.
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. In this section, the key trends and market size for each geography are provided over the period of 2016-2024. The countries covered in the North America region include the U.S., Canada, and Mexico; while Asia-Pacific includes China, Japan, India, South Korea, Malaysia, and among others. Moreover, Germany, U.K., France, Spain, and Rest of Europe are included in the European region. The U.S. drives the growth in the North America region as it is the largest market in the region. The Asia-pacific region offers a substantial potential for the market growth owing to rapid growth in markets such as India and China. The APAC region is projected to experience growth at a CAGR of x.x% over the period of 2018-2024.
The report provides profiles of the companies in the global hypercholesterolemia drugs market such as Aegerion Pharmaceuticals, Amgen Inc., AbbVie Inc., Eli Lilly, Merck & Co.Inc., Pfizer Inc., Sanofi S.A., Teva Pharmaceuticals, Cipla Limited, and Novartis.
The report provides deep insights on demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the global hypercholesterolemia drugs market. Moreover, IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of hypercholesterolemia drugs market. Moreover, the study highlights current market trends and provides forecast from 2018-2024. We also have highlighted future trends in the hypercholesterolemia drugs market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players. This report will help manufacturers, suppliers, and distributors of the hypercholesterolemia drugs market to understand the present and future trends in this market and formulate their strategies accordingly.
Get free analyst support for the queries before and post purchasing report.
Be assured of 100% customer satisfaction about the research and get 24X7 customer support.
Infinium has achieved over 400%+ growth in its repository and revenue over the last 2 years. Yes, we are proud to say we are growing at a great pace and becoming a trusted partner among our clients.
sign up for our newsletter